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Abstract 
Many people with an advanced form of kidney disease do not know they have weak or failing kidneys, but early 
detection and treatment can help prevent the progression of kidney disease to kidney failure. The resulting costs 
of treatment of ESRD are enormous. ESRD is a complex phenotype, which results from the presence of 
underlying kidney disease, and superimposing inherited and environmental factors. Among the predisposing 
genetic factors, renin-angiotensin-aldosterone system (RAAS) disruption is clearly involved in ESRD 
development. The aim of this study is to evaluate the association between CYP11B2 C-344T and ATR1 A1166C 
gene polymorphisms with increased risk for ESRD in hypertensive Egyptian patients on maintenance 
hemodialysis.  
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This study included 70 ESRD patients on maintenance hemodialysis (32 males and 28 females, mean age 54.5± 
9.5 years, recruited from El Doaah and El Rayan hospitals, Cairo, Egypt. 70 healthy individuals, of matching 
age and sex (30 males and 40 females, mean age 50.2 ± 13.1 years), were also included in the study. All subjects 
were genotyped for both CYP11B2 C-344T and ATR1 A1166C gene polymorphisms. Serum aldosterone was 
also measured for all subjects. Concerning the CYP11B2 gene, HD patients showed increased frequency of the 
TT genotype (68.57%) as compared to controls (only 12.85%), with no significant differences in T allele 
distribution between the 2 groups. In contrast, HD patients had low frequency of the CC genotype (5.71%) as 
compared to controls (32.85%), with a significant difference in C allele distribution between the HD patients 
(28.56%) and controls (70.7%). Comparing serum aldosterone levels in various CYP11B2 genotypes in HD 
patients revealed that patients with TT genotype had statistically higher aldosterone levels (121.583 ± 43.311) 
than those with the TC (72.055 ± 11.709) or CC genotype (68.75 ± 13.145). On the other hand, for AT1R A1166C 
genotype frequency, HD patients showed significantly (p˂0.05) higher frequency of CC genotype (70%) than 
controls (7.1%), with lower AA genotype frequency (5.71%) compared to controls (57%). Moreover, there was 
significant differences in A allele distribution between the HD patients (27.13%) and controls (64.25%).  The 
same was true for the C allele, with a frequency of (59.28%) in HD patients compared to a frequency of 
(39.25%) in controls. On the other hand, studying ATR1 A1166C gene polymorphisms revealed that patients 
with the CC genotype had significantly higher aldosterone levels (121.25 ± 43.006) than those with AA (87.6 ± 
25.4) genotype.  
Keywords: End stage renal disease; CYP11B2 C-344T; ATR1 A1166C; gene polymorphisms. 
1. Introduction  
Nephropathies of any etiology tend to progress to end-stage renal disease (ESRD) more or less rapidly over 
time. Many people with an advanced form of kidney disease do not know they have weak or failing kidneys, but 
early detection and treatment can help prevent the progression of kidney disease to kidney failure. The resulting 
are enormous. ESRD is a complex phenotype, which results from the presence of underlying kidney disease, and 
superimposing inherited and environmental factors [1]. Among the predisposing genetic factors, renin-
angiotensin-aldosterone system (RAAS) disruption is clearly involved in ESRD development [2]. The RAAS is 
a key blood pressure, renal hemodynamics, and volume homeostasis regulator [3]. Thus, genes that encode 
RAAS components are candidates for evaluating predisposition to renal disease development and progression 
[4]. 
Several studies have identified RAAS gene mutations and polymorphisms that affected host susceptibility to 
several diseases, including type 2 diabetes [5], myocardial infarction [6], chronic kidney disease, ESRD and 
hypertension [7].  Hypertension is the major contributor in the progression of renal failure in patients with renal 
disease both with and without proteinuria [8].  Moreover, hypertension per se is a risk factor for the 
development of ESRD [9-10].  On the other hand, the prevalence of hypertension increases with decreasing 
renal function [11]. This results from both a decreased sodium excretion and an activation of the renin-
angiotensin-aldosterone system (RAS). Therefore it is possible that a genetic predisposition to salt-dependent 
hypertension or over activation of the RAS may: 1-predispose to the development of renal failure and 2-promote 
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a more rapid loss of glomerular filtration rate in patients suffering from renal diseases.  Thus genes that regulate 
renal sodium reabsorption or genes of the RAS may be extremely important in patients suffering from ESRD. 
Among the candidate genes of the RAS, the aldosterone synthase gene (CYP11B2) and angiotensin II type I 
receptor (ATR1) are of particular interest [12]. 
Angiotensin II is the major biologically active product of RAAS, formed from its original precursor, 
angiotensinogen by two successive enzymatic cleavages. Angiotensin II acts as a potent vasoconstrictor and 
exerts its effects through two structurally different receptor subtypes: angiotensin II type 1 receptor and 
angiotensin II type 2 receptor. Angiotensin II type 1 receptor mediates most of the known biological effects of 
angiotensin II.  ANG II acts on ANG II type 1 receptors in the adrenal gland and enhances Aldosterone 
secretion [13].  
The gene coding for angiotensin II type 1 receptor is localized to chromosome 3q21q25, spans 45.123 kb and 
comprises 5 exons, the first four exons represent the 5′-UTR, whereas exon 5 harbored coding region [14]. 
Several polymorphic sequence variants have been found on angiotensin II receptor type 1 (ATR1) gene. The 
most well studied polymorphism is A1166C (rs5186), a transversion at position 1166 which is located in the 3′-
UTR of the ATR1 gene [15].  The ATR1 1166-C allele has been associated with increased risk for coronary 
artery disease, ischemic stroke, heart failure, and hypertension [16].  
Another important component of the Raas system is aldosterone synthase (18-hydroxylase or cytochrome P450 
11B2). It is a mineralocorticoid synthesized from deoxycorticosterone in the zona golmerulosa of the adrenal 
cortex by a mitochondrial cytochrome P450 enzyme [17]. Aldosterone synthase plays a major role in the 
regulation of sodium-water homeostasis, intravascular volume and blood pressure [18].  Several lines of 
evidence have demonstrated the role of high plasma aldosterone level in hypertension and progression of kidney 
diseases [19]. The gene coding for aldosterone synthase (CYP11B2) is located on chromosome 8q and contain 9 
exons. Several polymorphic variants have been identified in the CYP11B2 gene [20]. The promoter 
polymorphism (-344T/C: rs1799998), has been identified to alter aldosterone production, leading to sodium 
wasting and decreased excretion of potassium [21]. Initial studies have reported a positive association between -
344T allele and essential hypertension [22].  
The aim of this study is to evaluate the association between CYP11B2 and ATR1 gene polymorphisms with 
increased risk for ESRD in hypertensive Egyptian patients on maintenance hemodialysis. 
2. Patients 
This study included 70 ESRD patients on maintenance hemodialysis, recruited from El Doaah and El Rayan 
hospitals, Cairo, Egypt.  The work was done after taking acceptance of all patients and controls to share in the 
study as well as acceptance of ethics committee of Ain Shams University. The work has been carried out in 
accordance with the code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments 
involving humans. The controls (n=70) were individuals who have had no medical history of kidney disease and 
were normal in blood pressure, blood chemistry, urinalysis, and electrocardiogram (EKG). Basic demographic 
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data, current blood pressure, information on underlying renal disease, and current antihypertensive medication 
(data not shown) were obtained for all ESRD subjects.  
3. Methods 
3.1. Genotyping of the CYP11B2 C-344T gene polymorphism 
DNA was extracted from whole blood using a QIAamp Blood mini-prep Kit (QIAGEN, Germany) according to 
manufacturer’s instructions. Genotypes were determined by polymerase chain reaction (PCR) amplification of 
the promoter region of the CYP11B2 gene using the oligonucleotide primers (upstream: 5'-CAG 
GAGGAGACCCCATGTGAC-3'; downstream: 5'-CCTCC ACCCTGTTCAGCCC-3').  PCR conditions were: 
initial denaturation at 94˚C for 3 min; then 32 cycles at 94 ˚C for 1 min, at 60˚ C (annealing) for 1 min, and at 72 
˚C (extension) for 1 min. Restriction fragment length polymorphism (RFLP) was performed by adding 10 U of 
restriction endonuclease HaeIII site in the appropriated buffer to 5 μL from each reaction (a 537 bp product) and 
by incubating at 37 C for 2 hours. The digested samples then underwent gel electrophoresis, stained with 
ethidium bromide, and analyzed under UV lights. Since the (-344) T allele lacks an HaeIII site (GGCC) present 
in the (-344) C allele, the (-344) T alleles are detected as fragments of 273 bp and (-344) C alleles as fragments 
of 202 bp (plus smaller fragment in each case). 
3.2. Genotyping of the ATR1 A1166C gene polymorphism 
The A1166C variant of the AT1R gene was identified with primers: forward: 5’-
GCAGCACTTCACTACCAAATGGGC-3’ and reverse: 5’-CAGGACAAAAGCAGGCTAGGGAGA-3’. The 
reaction conditions were: The initial denaturation at 95˚C was followed by 35 cycles of denaturation at 94˚C, 
annealing at 55˚C and elongation at 72˚C, 1 min each. Final extension was at 72˚C for 7 min. The PCR products 
were digested with BsuRI restriction enzyme (MBI Fermentas, St. Leon-Rot, Germany). In the presence of 
cytosine there is a restriction site for this enzyme, resulting in a fragment 231 bp (C allele). Undigested 255 bp 
fragment indicates the presence of the A allele. 
3.3. Measurement of serum aldosterone 
Serum aldosterone was measured by radioimmunoassay for the in vitro determination of aldosterone in human 
serum, plasma and urine (Immunotech, A Beckman Coulter Company, IM1664). The radioimmunoassay of 
aldosterone is a competition assay. Samples and calibrators were incubated with an 125I-labeled aldosterone, as 
tracer, in antibody-coated tubes. After incubation, the liquid contents of the tube were aspirated and bound 
radioactivity is measured. A standard curve was established and unknown values were determined by 
interpolation from a standard curve. 
3.4. Statistical analyses 
The results were analyzed using the Statistical Package of Social Sciences (SPSS) computer software program, 
version 21.0 (Chicago, IL, USA). Quantitative data were presented as mean ± SD for normally distributed data. 
Qualitative data were presented in the form of frequencies and percentages. Differences among groups were 
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tested using Pearson’s chi-square test (χ2). A P value less than 0.05 was considered statistically significant. 
4. Results 
Table 1: Baseline characteristics of controls and ESRD patients 
parameter Age (years) 
(mean± SD) 
Gender 
Male/female 
Serum 
Aldosterone 
(pg/ml) 
Serum 
creatinine 
(mg/dL) 
Blood urea 
(mg/dL) 
Controls 
(n=70) 
50.2 ± 13.1 30/40 80.79 ± 17.37 0.82 ± 0.35 16.5±2.3 
HD patients 
(n=70) 
54.5± 9.5 32/28 105.83 ± 43.23 7.5±2.9 140.5±33.1 
P- value NS NS P˂ 0.001 P˂ 0.001 P˂ 0.001 
 
Table 2: CYP11B2 genotype frequency in patients and controls 
 ESRD Control P value 
TT 48 (68.57%) 9 (12.85%) p˂0.001 
TC 18 (25.71%) 38 (54.28%) p˂0.001 
CC 4 (5.71%) 23 (32.85%) p˂0.001 
 
Table 3: CYP11B2 allele frequency in patients and controls 
 ESRD Control P value 
T allele 42 (59.995 %) 43 (60.68 %) NS 
C allele 20 (28.565 % ) 50 (70.7 %) p˂0.05 
 
Table 4: ATR1 Genotype frequency in patients and controls 
 ESRD Control P value 
AA 4 (5.71%) 40 (57%) p˂0.05 
AC 17 (24.28%) 25 (35.7%) NS 
CC 49 (70%) 5 (7.1%) p˂0.05 
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Table 5: ATR1 allele frequency in patients and controls 
 ESRD control P value 
A allele 19 (27.135%) 45 (64.25%) p˂0.05 
C allele 42 (59.28%) 27 (39.25% ) p˂0.05 
 
Table 6: Comparison between mean serum aldosterone levels in different CYP11B2 genotypes in ESRD 
patients 
 N Mean±SD 
 
vs. TT 
 
vs. TC 
 
serum 
aldosterone 
TT 48 121.583 ± 43.311   
TC 18 72.055 ± 11.709 
p˂0.001** 
 
 
CC 4 68.75 ± 13.145 
p˂0.05* 
 
NS 
 
         *, ** = Significant and highly significant difference, respectively. 
 
Table 7: Comparison between mean serum aldosterone levels in different ATR1 genotypes in ESRD patients 
 N Mean±SD 
 
vs. AA 
 
vs. AC 
 
serum 
aldosterone 
AA 4 87.6 ±  25.4   
AC 17 99.024±   43.177 
NS 
 
 
CC 49 121.25±  43.006 
p˂0.05* 
 
NS 
 
* = significant difference 
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5. Discussion 
In the present study, there was a statistical evidence for significant interactions between genetic polymorphisms 
in ATR1 and CYP11B2 gene polymorphisms with ESRD risk.  
The present study was designed to investigate the association of CYP11B2 and ATR1 A1166C gene 
polymorphisms with ESRD. In this case-control study, significant differences could be observed in genotype 
and allele frequency of the CYP11B2 -344C/T as well as the AT1R A1166C polymorphisms between controls 
and ESRD patients. Concerning the CYP11B2 gene, HD patients showed increased frequency of the TT 
genotype (68.57%) as compared to controls (only 12.85%), with no significant differences in T allele 
distribution between the 2 groups. In contrast, HD patients had low frequency of the CC genotype (5.71%) as 
compared to controls (32.85%), with a significant difference in C allele distribution between the HD patients 
(28.56%) and controls (70.7%). Comparing serum aldosterone levels in various CYP11B2 genotypes in HD 
patients revealed that patients with TT genotype had statistically higher aldosterone levels (121.583 ± 43.311) 
than those with the TC (72.055 ± 11.709) or CC genotype (68.75 ± 13.145). This might explain the significant 
association between the TT genotype with ESRD.  
Our results are in contrast to reference [23] whose findings didn't support the hypothesis that CYP11B2 
polymorphism may be associated with prevalence of ESRD. 
Previous studies performed in Europe showed inconsistent results. Lovati and his colleagues [24] reported that 
there was no association between the CYP11B2 genotype and progression of renal failure among the ESRD 
patients. On the other hand, reference [25] reported that significant association was found between the 
CYP11B2 gene polymorphism and renal insufficiency in the hypertensive population. They observed an 
increased proportion of CC genotype in hypertensive patients with renal damage compared with hypertensive 
patients without renal damage.  In contrast, the current results are in agreement with a study by Su and his 
colleagues [26], where significant associations were found in the CYP11B2 C- 344T polymorphism between 
control and ESRD groups. For CYP11B2 C-344T, the CC genotype compared with the TT genotype was a 
protective factor for ESRD (𝑃𝑃 = 0.007).  
Song and his colleagues in [27] have also found that CYP11B2 C-344T polymorphism was associated with 
renal dysfunction progression, but only in female patients with IgA nephropathy. The C-344T polymorphism 
was a risk factor for accelerated progression in a Polish population with primary chronic glomerulonephritis 
[28]. 
On the other hand, for AT1R A1166C genotype frequency, HD patients showed significantly (p˂0.05) higher 
frequency of CC genotype (70%) than controls (7.1%), with lower AA genotype frequency (5.71%) compared 
to controls (57%). Moreover, there were significant differences in A allele distribution between the HD patients 
(27.13%) and controls (64.25%).  The same was true for the C allele, with a frequency of (59.28%) in HD 
patients compared to a frequency of (39.25%) in controls. 
On the other hand, studying ATR1 A1166C gene polymorphisms revealed that patients with the CC genotype 
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had significantly higher aldosterone levels (121.25 ± 43.006) than those with AA (87.6 ± 25.4) genotype, which 
explain the significantly increased frequency of CC genotype in HD patients than controls. 
The current results are in agreement with the study by [12], on AT1R A1166C, in which HD patients showed 
decreased frequency of the wild (AA) genotype and increased frequency of heterotype (AC) and mutant (CC) 
type than the corresponding control values. The authors have also observed that in the whole HD patients, A 
allele had significantly lower frequency compared to controls, with significantly increased C frequency 
compared to controls.  
In agreement with the current results is also the study by Hammady and his colleagues [29], where authors have 
found that AT1R 1166 AC genotype was significantly higher in hypertensives than normotensives, while AA 
was significantly higher in normotensive than hypertensives. Risk estimate for ATR1 A1166C AC genotype 
showed 8.5 times more risk for Hypertension than AA genotype. Authors have found that AC genotype 
frequency of AT1R gene is higher in CRF patients group versus control group while control group had higher 
AA genotype frequency versus CRF group, yet this difference did not reach a statistical significance. Authors 
have also found that C allele frequency was higher in CRF patients group versus control group, while A allele 
frequency was higher in control group versus CRF group, yet this difference did not reach a statistical 
significance.   
The current results as well as previous results about ATR1 gene can be explained in light of the findings of 
Chandra and his colleagues [30], who revealed that the expression of ATR1 gene was higher in patients with 
CC genotypes as compared to AC and AA.  Ceolotto and his colleagues  [31], have also observed an increased 
protein expression (70%) in patients with CC genotype, which leads to increased aldosterone levels.  
A1166C of ATR1 is located within the 3′ untranslated regions of the gene. Though this polymorphism does not 
lead to amino acid substitution, these 3′ untranslated regions may play a pivotal role in the genomic context of 
the genes and may influence their expression levels, since they could result in defects in messenger RNA 
(mRNA) processing, mRNA half-life, or affect the function of regulatory elements such enhancers and 
insulators [32-33]. Moreover, Sethupathy and his colleagues [34], have shown that there is a miRNA from 
chromosome 21, namely miR155, that down regulates the expression of the 1166A allele but not of the 1166C, 
hence, they hypothesize that the 1166C allele is associated with hypertension. 
6. Conclusion 
In conclusion, our findings support the hypothesis that both CYP11B2 TT and AT1R CC genotypes, are related 
to higher aldosterone levels and, hence, should be considered as risk factors for developing ESRD in 
hypertensive patients. Further studies are needed to investigate the relation between aldosterone levels and 
AGRT1 gene expression in relation to different ATR1 gene polymorphisms as well as to miR155. 
7. Limitations of the study 
Small sample size is a limitation in this study.  
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8. Recommendations 
Further studies with a greater sample size, are needed. It is also recommended to investigate the association 
between miR155 and AGRT1 gene expression in different AGRT1 gene polymorphisms, and determine its 
impact on aldosterone levels. 
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